A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 19, 2025

Primary Completion Date

November 2, 2025

Study Completion Date

November 9, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

TPIP F2

Inhalation using a capsule-based dry powder inhaler device.

DRUG

TPIP F3

Inhalation using a capsule-based dry powder inhaler device.

Trial Locations (1)

RECRUITING

USA001, Salt Lake City

All Listed Sponsors

lead

Insmed Incorporated

INDUSTRY